The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10623 malaria professionals are enjoying the free benefits of MalariaWorld today

naphthoquine

NOT Open Access | Evaluation of the combination of azithromycin and naphthoquine in animal malaria models

August 26, 2020 - 14:41 -- NOT Open Access
Author(s): 
Bei ZC, Li GF, Zhao JH, Zhang M, Ji XG, Wang JY
Reference: 
Antimicrob Agents Chemother. 2020 Aug 24

Combination therapy using drugs with different mechanisms of action is the current state of the art in antimalarial treatment. However, except for artemisinin-based combination therapies, only few other combinations are available now. The increasing concern on the emergence and spread of artemisinin resistance in Plasmodium falciparum has evoked a need for the development of new antimalarials.

The gender-related variability in the pharmacokinetics and antiplasmodial activity of naphthoquine in rodents

February 17, 2020 - 14:31 -- Open Access
Author(s): 
Yuewu Xie, Huixiang Liu, Yanhong Sun and Jie Xing
Reference: 
Malaria Journal 2020 19:71, 13 February 2020

Naphthoquine (NQ) is a suitable partner anti-malarial for the artemisinin-based combination therapy (ACT), which is recommended to be taken orally as a single-dose regimen. The metabolism of NQ was mainly mediated by CYP2D6, which is well-known to show gender-specific differences in its expression. In spite of its clinical use, there is limited information on the pharmacokinetics of NQ, and no data are available for females. In this study, the effect of gender on the pharmacokinetics and antiplasmodial efficacy of NQ in rodents was evaluated. The underlying factors leading to the potential gender difference, i.e., plasma protein binding and metabolic clearance, were also evaluated.

Subscribe to RSS - naphthoquine